2007 Fiscal Year Final Research Report Summary
Effect of Dehydroepiandrosterone on Atherosclerosis in Apolipoprotein E-Deficient Mice
| Project/Area Number |
18590820
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | YOKOHAMA CITY UNIVERSITY |
|---|
Principal Investigator |
YAMAKAWA Tadashi YOKOHAMA CITY UNIVERSITY, Medical Center, Departement of Endocrinology and Diabetes, asssistant Professor (30264641)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KISHIKAWA Seigo Azabu University, College of Environmental Health, Department of Pathology, asssistant Professor (10099377)
TERAUCHI Yasuo Yokohama City University, School of Medicine Department of Endocrinology and Metabolism, Professor (40359609)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | dehydroepiandrosterone / atherosclerosis / monocyte chemoattractant protein-1 / macrophage / apolipoportein E-knockout mice / MCP-1 |
|---|
| Research Abstract |
Aim : Several clinical trials have indicated that dehydroepiandrosterone (DHEA) reduces coronary events associated with atherosclerosis. The aim of this study was to examine the inhibitory effect of DHEA on atherosclerosis and the mechanisms involved. Methods : Apolipoprotein E-knockout (apoE-KO) mice were fed an atherogenic high-cholesterol diet with or without 0.4% (w/w) DHEA for 12 weeks.
Results : Although the plasma cholesterol and triglyceride levels were not decreased by DHEA. atherosclerotic lesions in the aortic sinus showed a 45% reduction in area with DHEA treatment versus untreated mice. Accumulation of macrophages in aortic lesions was also markedly reduced in the DHEA group. Furthermore. DHEA suppressed the expression of monocyte chemoattractant protein-1 in the vessel wall. Thus, inhibition of macrophage infiltration by DHEA reduced the formation of atherosclerotic lesions in apoE-KO mice.
Conclusions : DHEA might be an effective agent for clinical management of atherosclerosis, but a larger controlled trial is necessary for confirmation.
|
